New combo therapy aims to shrink lung tumors before surgery
NCT ID NCT07286942
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a new approach for people with early-stage non-small cell lung cancer that can be removed with surgery. Before surgery, patients receive a combination of targeted radiation (SBRT), two immunotherapy drugs (iparomlimab and tuvonralimab, also called QL1706), and chemotherapy. The goal is to see if this treatment can make the tumor disappear completely by the time of surgery. The study will enroll 24 adults in China and will also track side effects and long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a pill plus immunotherapy and targeted radiation shrink lung tumors before surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?